MitraClip Versus Surgery for Secondary Mitral Regurgitation: A Systematic Review and Updated Meta‐Analysis
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.70114 ↗At a glance
Systematische Übersicht in Catheterization and Cardiovascular Interventions, 2025. Written by Juan Pinilla and 8 co-authors. Institution: CES University, School of Medicine, Medellín, Colombia. Major MEDLINE topics: Cardiac Catheterization, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Mitral Valve. 39 references. Funded by: The authors received no specific funding for this work..
Abstract (original language)
Background
The optimal management of secondary mitral regurgitation (MR) remains uncertain, with surgical and percutaneous approaches offering alternative treatment strategies.
Aim
To compare percutaneous repair with mitral transcatheter edge‐to‐edge repair (M‐TEER) using MitraClip and surgical intervention in patients with secondary MR.
Methods
We systematically searched PubMed, Embase, and Cochrane for studies comparing M‐TEER using MitraClip with surgery in secondary MR, reporting outcomes of interest. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using a random‐effects model in R software. Heterogeneity was assessed with I² statistics.
Results
A total of 11 studies (two randomized controlled trials and nine observational studies) comprising 1605 patients were included. The mean age was 69 years. Among them, 906 (57.7%) underwent MitraClip. Mean follow‐up was 24.7 months (minimum: 6 months). The rate of MR grade ≤ 2+ at follow‐up was lower in the MitraClip group compared to surgery (RR: 0.86, 95% CI: 0.78 to 0.95, p < 0.01). No significant differences were observed in all‐cause mortality (RR: 1.18, 95% CI: 0.93 to 1.49, p = 0.16), cardiovascular mortality (RR: 1.42, 95% CI: 0.54 to 3.68, p = 0.47), heart failure hospitalizations (RR: 1.55, 95% CI: 0.79 to 3.04, p = 0.20), or NYHA class I/II at follow‐up (RR: 0.92, 95% CI: 0.83 to 1.01, p = 0.08).
Conclusion
Although patients undergoing MitraClip exhibited a lower rate of residual MR ≤ 2+ at follow‐up compared to those treated surgically, this did not translate into higher rates of clinical outcomes, including all‐cause mortality, cardiovascular mortality, heart failure hospitalizations, or impaired functional status (NYHA classification).
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- CES University, School of Medicine, Medellín, Colombia.
- Facultad de Ciencias Biomédicas, Universidad Austral, Pilar, Buenos Aires, Argentina.
- Instituto de Investigación Nutricional, Lima, Peru.
- Universidad Autónoma Metropolitana, Mexico City, Mexico.
- Birat Medical College and Teaching Hospital, Biratnagar, Nepal.
- Department of Medicine, Catholic University of Pernambuco.
ORCID profiles: Juan Pinilla, Sebastian Jaramillo, Mariano Gallo Ruelas, Miguel Samaniego, Brijesh Baral, Nyree Nava, Ivo Queiroz, Fabio R Farias, Philippe Garot
Funding
- The authors received no specific funding for this work.
Cite
APA
Pinilla, J., Jaramillo, S., Gallo Ruelas, M., Samaniego, M., Baral, B., Nava, N., Queiroz, I., R Farias, F., & Garot, P. (2025). MitraClip Versus Surgery for Secondary Mitral Regurgitation: A Systematic Review and Updated Meta‐Analysis. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70114
Vancouver
Pinilla J, Jaramillo S, Gallo Ruelas M, Samaniego M, Baral B, Nava N, et al. MitraClip Versus Surgery for Secondary Mitral Regurgitation: A Systematic Review and Updated Meta‐Analysis. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70114
BibTeX
@article{Pinilla2025,
author = {Pinilla, Juan and Jaramillo, Sebastian and Gallo Ruelas, Mariano and Samaniego, Miguel and Baral, Brijesh and Nava, Nyree and Queiroz, Ivo and R Farias, Fabio and Garot, Philippe},
title = {MitraClip Versus Surgery for Secondary Mitral Regurgitation: A Systematic Review and Updated Meta‐Analysis},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.70114}
}
EUVIMED